Beyond Half-Life: Six Routes to Longer-Acting Peptide Therapeutics

Beyond Half-Life: Six Routes to Longer-Acting Peptide Therapeutics

Extending the half-life of a peptide is not always the same as extending its therapeutic value. The more relevant development goal is to create an exposure profile that supports the intended pharmacology, dosing interval, and therapeutic window.

Why effective exposure matters

When long-acting peptide drugs are discussed, half-life is usually the first parameter mentioned.

From a development perspective, however, I find it more useful to think in terms of effective exposure.

The objective is not simply to keep a molecule in circulation for as long as possible. It is to reduce dosing frequency, maintain pharmacological activity, and shape a PK/PD profile that remains aligned with the intended therapeutic window.

Figure 1. Long-acting design aims to maintain effective exposure within the therapeutic window, rather than simply maximizing circulating half-life.

This distinction matters because peptides can be limited in vivo for very different reasons.

Some are rapidly degraded by proteases. Some are cleared quickly through the kidneys because of their relatively small molecular size. Others reach an effective concentration but decline too rapidly, or are released too quickly from the administration site.

These are different problems, and they should not be approached with the same tool.

Long-acting peptide design should therefore begin with the dominant limitation of the molecule—not with a preferred technology platform.

In practice, the available approaches can be grouped into six broad routes.

1. Fatty-acid conjugation and albumin binding

Fatty-acid chains, albumin-binding groups, and other small-molecule ligands can enable reversible association with serum albumin.

This interaction increases the apparent size of the drug–albumin complex, slows renal filtration, and may provide partial protection from proteolytic degradation. The peptide can subsequently dissociate from albumin and interact with its pharmacological target.

This is one of the most mature and widely validated approaches in long-acting peptide drug development, particularly in the GLP-1 field.

Its performance, however, depends on more than the presence of a fatty-acid chain. The length and composition of the lipid, the conjugation site, linker design, albumin-binding affinity, and residual receptor activity all need to be considered together.

Strong albumin binding is not automatically optimal. The association must remain reversible enough to maintain an appropriate concentration of pharmacologically available peptide.

2. PEGylation and hydrophilic polymer modification

PEG and other hydrophilic polymers can increase the hydrodynamic size of a peptide, reduce glomerular filtration, and partially shield protease-sensitive regions.

Other polymers, including polyglycerol, polysarcosine, and polysialic acid, may serve related functions while offering different physicochemical or biological properties.

PEGylation is a well-established platform with a relatively clear development history. It can be particularly useful when a program needs to establish the feasibility of half-life extension using a technically familiar approach.

Nevertheless, polymer modification creates its own design questions.

Polymer size, architecture, conjugation site, product heterogeneity, biological activity, tissue distribution, and tolerability must all be evaluated for the individual molecule. Increasing hydrodynamic size can improve exposure, but it may also reduce receptor binding or alter tissue penetration.

The objective is therefore not simply to attach the largest possible polymer, but to identify a modification that improves exposure without compromising the intended pharmacology.

3. Fc, albumin, and polypeptide fusion technologies

Fusion to Fc or albumin can transform a short-lived peptide into a larger, long-circulating fusion molecule.

Both Fc and albumin can benefit from FcRn-mediated recycling, which protects the fusion protein from lysosomal degradation and returns it to the circulation.

Other fusion technologies use unstructured or repetitive polypeptide sequences such as XTEN, PAS, and ELP. These tags mainly extend circulation by increasing apparent molecular volume and hydrophilicity rather than by creating a conventional globular protein domain.

Fusion technologies can provide substantial exposure extension, but they also move the product into a different development and manufacturing space.

Recombinant expression, folding, aggregation, product heterogeneity, analytical characterization, immunogenicity, and biological activity all become important considerations.

These approaches are most suitable when the molecular design, expression system, and intended manufacturing process can be developed as an integrated product strategy.

4. Conformational stabilization and protease-resistant design

Not every peptide requires a large carrier or an external half-life extension group.

In many cases, the first problem is that the parent peptide itself is too susceptible to enzymatic cleavage or conformational instability.

Cyclization, D-amino-acid substitution, N-methylation, terminal capping, disulfide constraints, and the introduction of non-natural amino acids can improve resistance to proteolysis and help maintain the biologically active conformation.

This is often the first layer of long-acting peptide design.

Before adding a polymer, albumin-binding group, or complex formulation, it is worth asking whether the intrinsic stability of the peptide has been sufficiently optimized.

A more stable parent molecule can simplify later development and may reduce the degree of additional half-life extension required.

At the same time, molecular stabilization must preserve potency, selectivity, solubility, and synthetic feasibility. A modification that prevents enzymatic cleavage but significantly reduces receptor activity may not improve the overall product profile.

5. Long-acting formulations and depot delivery

Long-acting performance can also be created at the formulation level.

PLGA microspheres, implants, in situ gels, self-assembling hydrogels, and crystalline suspensions can retain the drug at the administration site and release it gradually over time.

These systems do not necessarily alter the intrinsic elimination half-life of the parent peptide.

Instead, they extend the absorption phase, smooth the concentration–time profile, and maintain effective exposure over a longer period.

This distinction is important. A product may provide weekly or monthly pharmacological coverage even though the released peptide itself still has a relatively short systemic half-life.

Depot delivery can be especially valuable when a substantial reduction in dosing frequency is required. However, it introduces formulation-specific challenges, including burst release, loading capacity, peptide stability within the formulation, release reproducibility, injection volume, local tolerability, and scale-up.

The formulation must therefore be evaluated as part of the drug product—not simply as a container for the peptide.

6. Prodrug strategies and reversible linkers

A peptide can also be temporarily masked, conjugated to a carrier, or connected through a reversible linker so that the active parent molecule is generated gradually in vivo.

This approach may preserve the original pharmacology of the parent peptide while changing the rate at which it becomes available.

The key question is not simply whether a molecule can be described as a prodrug.

The cleavage mechanism and release rate must be sufficiently predictable to create a meaningful and controllable exposure profile.

If the linker is cleaved too quickly, the design may provide little advantage over the unmodified peptide. If release is too slow or incomplete, the concentration of active drug may never reach the desired therapeutic range.

Linker stability during manufacturing, storage, administration, and systemic circulation must therefore be balanced against the intended activation mechanism.

Choosing the right strategy

Figure 2. A practical starting framework based on the dominant development limitation. Combination strategies may be required when several limitations coexist.

The first step in long-acting peptide development should be to identify the dominant limitation.

If the primary problem is proteolytic degradation, molecular stabilization may be the most direct starting point.

If the dominant issue is rapid renal clearance, albumin binding, hydrophilic polymer modification, or fusion technologies may be more appropriate.

If the objective is a substantial reduction in dosing frequency, a depot formulation may be required, even when the parent peptide itself remains short-lived.

If the aim is to preserve the structure and pharmacology of the parent molecule while generating it gradually in vivo, a prodrug or reversible-linker strategy may be suitable.

This framework is useful, but these categories are not mutually exclusive.

A peptide may require molecular stabilization first, followed by albumin binding to reduce clearance. A depot formulation may contain a peptide that has already been optimized against enzymatic degradation. A reversible linker may be combined with a long-circulating carrier.

The most appropriate design often combines two or more mechanisms.

Longer is not always better

The best design is rarely the one that produces the longest number on a PK curve.

Exposure must remain in the right range, for the right duration.

Extending exposure too aggressively can increase accumulation, prolong adverse effects, reduce dose flexibility, or create a PK profile that no longer matches the underlying pharmacology.

The appropriate exposure profile depends on the target, mechanism of action, receptor kinetics, tissue distribution, therapeutic window, and intended patient population.

Manufacturability must also be considered early.

A technically elegant molecule may still face challenges if it produces complex impurity profiles, unstable linkages, difficult purification, poor formulation behaviour, or analytical methods that cannot adequately control product quality.

For this reason, long-acting design should not be treated as a purely pharmacokinetic exercise.

It is a product-design problem that connects molecular engineering, formulation, pharmacology, safety, manufacturing, and quality control.

Final perspective

Long-acting peptide development is not about making every molecule circulate for as long as possible.

It is about building an exposure profile that is appropriate for the molecule, the target biology, and the intended product.

Fatty-acid conjugation, polymer modification, fusion technologies, molecular stabilization, depot delivery, and reversible-linker strategies each address different development limitations.

In many successful programs, the final product is not built around a single platform. It combines the right mechanisms into a design that is pharmacologically effective, technically explainable, manufacturable, and appropriately controlled.

The most robust strategy is usually not the one that maximizes a single PK parameter, but the one that achieves the best overall balance between exposure, efficacy, safety, dosing convenience, molecular complexity, and product feasibility.

Selected reading

1. Half-life Extension of Therapeutics: Applications and Mechanisms. Journal of Pharmacology and Experimental Therapeutics, 2025.

2. Molecular Engineering Approaches to Half-life Extension of Therapeutic Biomolecules. Frontiers in Pharmacology, 2026.

3. Strategic Approaches to Optimizing Peptide ADME Properties. The AAPS Journal, 2015.

4. Recent Advances in Formulations for Long-Acting Delivery of Therapeutic Peptides. Pharmaceutics, 2023.

5. The Expanding Role of Prodrugs in Contemporary Drug Design and Development. Nature Reviews Drug Discovery, 2018.